"Radiopharmaceuticals" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that are used in medicine as sources of radiation for radiotherapy and for diagnostic purposes. They have numerous uses in research and industry. (Martindale, The Extra Pharmacopoeia, 30th ed, p1161)
| Descriptor ID |
D019275
|
| MeSH Number(s) |
D27.505.259.843 D27.505.519.871 D27.720.470.410.650
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Radiopharmaceuticals".
Below are MeSH descriptors whose meaning is more specific than "Radiopharmaceuticals".
This graph shows the total number of publications written about "Radiopharmaceuticals" by people in this website by year, and whether "Radiopharmaceuticals" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 1998 | 1 | 4 | 5 |
| 1999 | 1 | 2 | 3 |
| 2000 | 4 | 2 | 6 |
| 2001 | 2 | 1 | 3 |
| 2002 | 2 | 1 | 3 |
| 2003 | 0 | 1 | 1 |
| 2004 | 1 | 4 | 5 |
| 2006 | 2 | 1 | 3 |
| 2007 | 7 | 2 | 9 |
| 2008 | 0 | 1 | 1 |
| 2009 | 1 | 2 | 3 |
| 2010 | 2 | 2 | 4 |
| 2011 | 3 | 5 | 8 |
| 2012 | 2 | 6 | 8 |
| 2013 | 1 | 3 | 4 |
| 2014 | 4 | 2 | 6 |
| 2015 | 3 | 1 | 4 |
| 2016 | 2 | 9 | 11 |
| 2017 | 2 | 5 | 7 |
| 2018 | 3 | 5 | 8 |
| 2019 | 0 | 3 | 3 |
| 2020 | 6 | 5 | 11 |
| 2021 | 1 | 3 | 4 |
| 2022 | 0 | 5 | 5 |
| 2023 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Radiopharmaceuticals" by people in Profiles.
-
A simplified protocol for the automated production of 2-[18 F]fluoro-3-[2-((S)-3-pyrrolinyl)methoxy]pyridine ([18 F]nifene) on an IBA Synthera® module. J Labelled Comp Radiopharm. 2024 Jan; 67(1):31-36.
-
Prognostic Role of Biologically Active Volume of Disease in Patients With Metastatic Lung Adenocarcinoma. Clin Lung Cancer. 2023 05; 24(3):244-251.
-
The optimal 18F-fluoromisonidazole PET threshold to define tumor hypoxia in preclinical squamous cell carcinomas using pO2 electron paramagnetic resonance imaging as reference truth. Eur J Nucl Med Mol Imaging. 2022 Oct; 49(12):4014-4024.
-
Pearls and Pitfalls of 18FDG-PET Head and Neck Imaging. Neuroimaging Clin N Am. 2022 May; 32(2):287-298.
-
Imaging Cardiac Masses in Patients with Cancer. Isr Med Assoc J. 2022 Mar; 24(3):186-190.
-
Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI) Versus the Standard of Care Imaging in the Diagnosis of Peritoneal Carcinomatosis. Ann Surg. 2023 04 01; 277(4):e893-e899.
-
Developing a clinical and PET/CT volumetric prognostic index for risk assessment and management of NSCLC patients after initial therapy. Front Biosci (Landmark Ed). 2022 01 12; 27(1):16.
-
The influence of conditioned stimuli on [11C]-(+)-PHNO PET binding in tobacco smokers after a one week abstinence. Sci Rep. 2021 06 03; 11(1):11667.
-
Proton MR Spectroscopy Measurements of White and Brown Adipose Tissue in Healthy Humans: Relaxation Parameters and Unsaturated Fatty Acids. Radiology. 2021 05; 299(2):396-406.
-
Multimodality In Vivo Imaging of Perfusion and Glycolysis in a Rat Model of C6 Glioma. Mol Imaging Biol. 2021 08; 23(4):516-526.